RA
MCID: RHM011
MIFTS: 82

Rheumatoid Arthritis (RA)

Categories: Bone diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Rheumatoid Arthritis

MalaCards integrated aliases for Rheumatoid Arthritis:

Name: Rheumatoid Arthritis 57 12 75 25 74 37 29 55 6 43 3 15 38 63 17 72
Ra 57 25 74 3
Arthritis, Rheumatoid 25 44 40
Rheumatoid Arthritis, Susceptibility to 57 13
Arthritis or Polyarthritis, Rheumatic 12
Atrophic Arthritis 12

Characteristics:

OMIM:

57
Inheritance:
unproved inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:7148
OMIM 57 180300
KEGG 37 H00630
ICD9CM 35 714.0
MeSH 44 D001172
NCIt 50 C2884
SNOMED-CT 68 69896004
MedGen 42 C0003873
UMLS 72 C0003873

Summaries for Rheumatoid Arthritis

Genetics Home Reference : 25 Rheumatoid arthritis is a disease that causes chronic abnormal inflammation, primarily affecting the joints. The most common signs and symptoms are pain, swelling, and stiffness of the joints. Small joints in the hands and feet are involved most often, although larger joints (such as the shoulders, hips, and knees) may become involved later in the disease. Joints are typically affected in a symmetrical pattern; for example, if joints in the hand are affected, both hands tend to be involved. People with rheumatoid arthritis often report that their joint pain and stiffness is worse when getting out of bed in the morning or after a long rest. Rheumatoid arthritis can also cause inflammation of other tissues and organs, including the eyes, lungs, and blood vessels. Additional signs and symptoms of the condition can include a loss of energy, a low fever, weight loss, and a shortage of red blood cells (anemia). Some affected individuals develop rheumatoid nodules, which are firm lumps of noncancerous tissue that can grow under the skin and elsewhere in the body. The signs and symptoms of rheumatoid arthritis usually appear in mid- to late adulthood. Many affected people have episodes of symptoms (flares) followed by periods with no symptoms (remissions) for the rest of their lives. In severe cases, affected individuals have continuous health problems related to the disease for many years. The abnormal inflammation can lead to severe joint damage, which limits movement and can cause significant disability.

MalaCards based summary : Rheumatoid Arthritis, also known as ra, is related to arthritis and autoimmune disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Rheumatoid Arthritis is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are Rheumatoid arthritis and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Etoricoxib and Dimethyl fumarate have been mentioned in the context of this disorder. Affiliated tissues include Cartilage, joint and bone, and related phenotypes are abnormality of the immune system and abnormality of the nervous system

Disease Ontology : 12 An arthritis that is an autoimmune disease which attacks healthy cells and tissue located in joint.

OMIM : 57 Rheumatoid arthritis is an inflammatory disease, primarily of the joints, with autoimmune features and a complex genetic component. (180300)

MedlinePlus : 43 Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness and loss of function in your joints. It can affect any joint but is common in the wrist and fingers. More women than men get rheumatoid arthritis. It often starts in middle age and is most common in older people. You might have the disease for only a short time, or symptoms might come and go. The severe form can last a lifetime. Rheumatoid arthritis is different from osteoarthritis, the common arthritis that often comes with older age. RA can affect body parts besides joints, such as your eyes, mouth and lungs. RA is an autoimmune disease, which means the arthritis results from your immune system attacking your body's own tissues. No one knows what causes rheumatoid arthritis. Genes, environment, and hormones might contribute. Treatments include medicine, lifestyle changes, and surgery. These can slow or stop joint damage and reduce pain and swelling. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. In a joint with RA, the lining of the joint becomes inflamed, causing damage to joint tissue. This tissue damage can cause long-lasting or chronic pain, unsteadiness (lack of balance), and deformity (misshapenness). RA can also affect other tissues throughout the body and cause problems in organs such as the lungs, heart, and eyes.

KEGG : 37
Rheumatoid arthritis (RA) is a common autoimmune disease that primarily manifests as chronic inflammatory arthropathy. Persistent synovitis leads to cartilage destruction, bone erosions and periarticular decalcification, subsequently resulting in impaired joint function. It is more common between the ages of 35 and 50 years, affecting three times more women than men. Susceptibility to RA is genetically determined with multiple genes contributing. Inheritance of HLA DRB1 alleles encoding a distinctive five-amino-acid sequence known as the "shared epitope" (SE) is the best characterized genetic risk factor. The mechanism by which the SE alleles contribute to the development of RA is not very clear. It has been postulated that the presence of these conserved sequences in the antigen-binding groove alters the way antigenic peptides are bound to and presented to T-cell lymphocytes. This, in turn, may trigger abnormal immune responses and lead to RA.

UniProtKB/Swiss-Prot : 74 Rheumatoid arthritis: An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.

PubMed Health : 63 About rheumatoid arthritis: There are many different rheumatic diseases, but rheumatoid arthritis is probably the most common. In rheumatoid arthritis, people usually have several permanently inflamed joints. This causes the joints to gradually become deformed and stiff. Over time the muscles also weaken. Someone with advanced rheumatoid arthritis may have difficulties with simple tasks such as washing themselves, eating with a knife and fork, or buttoning up a shirt. Other symptoms such as pain and fatigue can be very troublesome too. This disease can also affect other parts of the body, like the blood vessels or certain organs. Rheumatoid arthritis usually gradually worsens over the course of many years. Various treatments can relieve the pain and slow the progression of the disease. Early diagnosis and treatment can help to prevent damage to the joints.

Wikipedia : 75 Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically... more...

Related Diseases for Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2361)
# Related Disease Score Top Affiliating Genes
1 arthritis 35.2 PTPN22 IL6 IL10 CIITA
2 autoimmune disease 33.8 PTPN22 PADI4 IL6 IL10
3 bone inflammation disease 32.8 PTPN22 PADI4 IL6 IL10
4 psoriatic arthritis 32.6 PTPN22 MIR146A IL6
5 toxic shock syndrome 32.2 IL6 IL10 CIITA
6 multiple sclerosis 32.2 PADI4 IL6 IL10 CIITA
7 polymyositis 31.7 MIR155 MIR132
8 cholangiocarcinoma 31.5 UCA1 MALAT1 IL6 H19
9 coronary heart disease 1 31.3 MIR155 IL6 H19
10 chronic mucocutaneous candidiasis 31.3 PTPN22 IL6 IL10
11 ulcerative colitis 31.2 IL6 IL10 H19
12 pancreatic cancer 30.9 UCA1 MIR155 MIR146A MALAT1 HOTAIR H19
13 diffuse large b-cell lymphoma 30.7 MIR155 MIR150 HOTAIR
14 endometriosis 30.6 MIR150 IL6 H19
15 pre-eclampsia 30.5 MALAT1 IL6 IL10 HOTAIR H19
16 diabetes mellitus 30.2 PTPN22 MIR155 MIR132 MALAT1 IL6
17 ovarian epithelial cancer 30.1 MALAT1 HOTAIR H19
18 thyroid cancer, nonmedullary, 1 30.0 MIR155 MIR146A MALAT1 HOTAIR H19
19 myeloma, multiple 29.8 UCA1 MALAT1 IL6 HOTAIR H19
20 laryngeal squamous cell carcinoma 29.7 MALAT1 HOTAIR H19
21 gastric cardia adenocarcinoma 29.7 HOTAIR H19
22 kidney cancer 29.5 MIR150 MALAT1 HOTAIR H19
23 gastrointestinal system cancer 29.4 MALAT1 IL6 HOTAIR H19
24 pancreatic ductal adenocarcinoma 29.3 UCA1 MIR155 MIR150 MIR146A MALAT1 HOTAIR
25 pituitary adenoma 29.3 MIR132 MALAT1 HOTAIR H19
26 leukemia, acute myeloid 28.9 UCA1 MIR155 MIR146A MALAT1 HOTAIR
27 renal cell carcinoma, nonpapillary 28.9 UCA1 MALAT1 HOTAIR H19
28 osteogenic sarcoma 28.9 UCA1 MALAT1 HOTAIR H19
29 glioma 28.7 ZFAS1 UCA1 MALAT1 HOTAIR H19
30 bladder cancer 28.5 ZFAS1 UCA1 MALAT1 HOTAIR H19
31 gallbladder cancer 28.5 UCA1 MALAT1 HOTAIR H19
32 esophageal cancer 28.4 UCA1 MALAT1 IL6 HOTAIR H19
33 oral squamous cell carcinoma 27.9 UCA1 MIR155 MIR146A MALAT1 HOTAIR H19
34 gastric cancer 27.6 ZFAS1 UCA1 MIR150 MALAT1 HOTAIR H19
35 lung cancer 27.2 ZFAS1 UCA1 MIR155 MIR150 MIR146A MALAT1
36 ovarian cancer 27.2 ZFAS1 UCA1 MIR155 MIR150 MIR146A MALAT1
37 colorectal cancer 27.1 ZFAS1 UCA1 MIR155 MIR132 MALAT1 IL6
38 hepatocellular carcinoma 26.7 ZFAS1 UCA1 MIR155 MIR150 MIR146A MIR132
39 juvenile rheumatoid arthritis 13.1
40 rheumatoid arthritis, systemic juvenile 12.9
41 rheumatoid arthritis interstitial lung disease 12.9
42 ras-associated autoimmune leukoproliferative disorder 12.7
43 felty syndrome 12.5
44 sjogren syndrome 12.0
45 polyarticular onset juvenile idiopathic arthritis 11.9
46 rheumatoid vasculitis 11.9
47 arthropathy, progressive pseudorheumatoid, of childhood 11.9
48 adult-onset still's disease 11.9
49 carpal tunnel syndrome 11.9
50 fibromyalgia 11.8

Comorbidity relations with Rheumatoid Arthritis via Phenotypic Disease Network (PDN): (show all 32)


Active Peptic Ulcer Disease Acute Cystitis
Bronchiectasis Bronchitis
Chronic Rheumatic Pericarditis Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Esophagitis Felty Syndrome
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Idiopathic Interstitial Pneumonia Immune Deficiency Disease
Iron Deficiency Anemia Mononeuropathy of the Median Nerve, Mild
Neutropenia Olecranon Bursitis
Oral Candidiasis Osteoarthritis
Osteoporosis Perforated Corneal Ulcer
Postinflammatory Pulmonary Fibrosis Premature Ovarian Failure 7
Protein-Energy Malnutrition Scleritis
Sjogren Syndrome Spondyloarthropathy 1
Systemic Lupus Erythematosus Temporal Arteritis

Graphical network of the top 20 diseases related to Rheumatoid Arthritis:



Diseases related to Rheumatoid Arthritis

Symptoms & Phenotypes for Rheumatoid Arthritis

Human phenotypes related to Rheumatoid Arthritis:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 32 HP:0002715
2 abnormality of the nervous system 32 HP:0000707
3 vasculitis 32 HP:0002633
4 abnormality of the respiratory system 32 HP:0002086
5 abnormality of blood and blood-forming tissues 32 HP:0001871
6 rheumatoid arthritis 32 HP:0001370

Symptoms via clinical synopsis from OMIM:

57
Joints:
rheumatoid arthritis

Limbs:
rheumatoid nodules

Vascular:
rheumatoid vasculitis

Neuro:
rheumatoid vasculitic mononeuritis

Immunology:
hla-drb1 association

Pulm:
rheumatoid lung disease

Heme:
felty syndrome

Clinical features from OMIM:

180300

UMLS symptoms related to Rheumatoid Arthritis:


back pain, sciatica, muscle cramp

Drugs & Therapeutics for Rheumatoid Arthritis

PubMed Health treatment related to Rheumatoid Arthritis: 63

Rheumatoid arthritis is treated with both medication and non-drug approaches, such as physiotherapy. There are also various support aids available for making everyday tasks easier. Which of these treatments are suitable options will depend on, for example, how severe the inflammation and the symptoms are, how advanced the disease is, the expected progression of the disease – and how well previous treatments have worked. Medication can reduce inflammation and help keep the disease from getting worse,relieve symptoms like pain and swelling, andhelp people move their joints more easily again, or at least maintain joint flexibility for as long as possible. There is currently no cure for rheumatoid arthritis. Physiotherapy and sports can help improve or maintain flexibility, strength and joint function. Many types of sports are suitable for people who have rheumatoid arthritis, including cycling, brisk walking, dancing, aerobics, strength training, swimming and water aerobics. Occupational therapy can be used to maintain your flexibility and hand strength, and to learn how to cope with rheumatoid arthritis in everyday life. Psychological treatments are also sometimes used to help relieve pain and minimize the impact it has on everyday life. They are also intended to help relieve disease-related anxiety and depression that some people develop. Support aids are designed to help compensate for physical limitations and help with daily activities. These include orthopedic shoe inserts, grabbing aids and specially designed cutlery.

Drugs for Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 713)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
2
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Dinoprostone Approved Phase 4 363-24-6 5280360
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
13
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Ticagrelor Approved Phase 4 274693-27-5 9871419
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
18
Norepinephrine Approved Phase 4 51-41-2 439260
19
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21 Orange Approved Phase 4
22
Promethazine Approved, Investigational Phase 4 60-87-7 4927
23
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
25
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
26
Pheniramine Approved Phase 4 86-21-5 4761
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
29
alemtuzumab Approved, Investigational Phase 4 216503-57-0
30
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
31
Pancrelipase Approved, Investigational Phase 4 53608-75-6
32
Aceclofenac Approved, Investigational Phase 4 89796-99-6
33
Codeine Approved, Illicit Phase 4 76-57-3 5284371
34 Strawberry Approved Phase 4
35 Artichoke Approved Phase 4
36
Anthralin Approved Phase 4 1143-38-0
37
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
38
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
39
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
40
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
41
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
42
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
43
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
44
Infliximab Approved Phase 4 170277-31-3
45
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
46
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
47
Ocrelizumab Approved, Investigational Phase 4 637334-45-3
48
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
49
Racepinephrine Approved Phase 4 329-65-7 838
50
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754

Interventional clinical trials:

(show top 50) (show all 3054)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
3 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
4 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
5 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
6 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis. Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
7 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4 infliximab, etanercept, adalimumab;abatacept, rituximab or tocilizumab
8 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
9 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
10 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
11 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
12 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
13 A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis Unknown status NCT02780323 Phase 4 CELBESTA®;CELEBREX®;CELEBREX® placebo;CELBESTA® placebo
14 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
15 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
16 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
17 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
18 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
19 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
20 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
21 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
22 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
23 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
24 A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
25 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
26 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
27 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
28 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
29 Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept Unknown status NCT02353780 Phase 4 TNF Antagonist (enbrel, humire, remicade, cimzia, symponi);Abatacept;Tocilizumab
30 A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis Unknown status NCT01303874 Phase 4 Etanercept (ETN);Placebo
31 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
32 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
33 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
34 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
35 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
36 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
37 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
38 The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction Unknown status NCT01372930 Phase 4 Etanercept;saline
39 Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome Unknown status NCT02241148 Phase 4 Acetaminophen 500mg
40 A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis Unknown status NCT00808496 Phase 4
41 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
42 Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase Unknown status NCT00525993 Phase 4 etoricoxib 90mg 14 days;etoricoxib 60mg daily for 14 days
43 Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO) Completed NCT00234897 Phase 4 adalimumab
44 A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA) Completed NCT01554917 Phase 4 Iguratimod
45 A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate Completed NCT00913458 Phase 4 etanercept
46 An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs Completed NCT01511003 Phase 4 Tacrolimus
47 An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects Completed NCT00252668 Phase 4 Etanercept;Methotrexate
48 A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy Completed NCT00244556 Phase 4 Methotrexate plus ENBREL or ENBREL alone
49 Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study Completed NCT01224418 Phase 4 Tacrolimus
50 Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study Completed NCT01224041 Phase 4 Tacrolimus

Search NIH Clinical Center for Rheumatoid Arthritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


ACETYLSALICYLATE SODIUM
Acetylsalicylic acid
adalimumab
anakinra
Aspirin
ASPIRIN PWDR
Auranofin
Auranofin
Aurothioglucose
Azathioprine
Azathioprine
Betamethasone
Bupivacaine
Captopril
celecoxib
Celecoxib
Chloroquine
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
Choline magnesium trisalicylate
choline salicylate
Corticotropin
Cortisone acetate
Cyclosporine
Dexamethasone
Diclofenac
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Diflunisal
Enalapril
Enalapril Maleate
Enalaprilat
Etanercept
Etanercept
Etodolac
Etodolac
Fenoprofen
Fenoprofen
Fenoprofen Calcium
Fish Oils
Flurbiprofen
Flurbiprofen
Flurbiprofen sodium
Gold
Gold Sodium Thiomalate
Hydrocortisone
Hydrocortisone acetate
Hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine Sulfate
Ibuprofen
Ibuprofen
Indomethacin
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Infliximab
Ketoprofen
Ketoprofen
KETOPROFEN PWDR
leflunomide
Leflunomide
Linoleic acid
Meclofenamic acid
Meloxicam
Methotrexate
Methotrexate Sodium
Methylprednisolone
nabumetone
Nabumetone
Naproxen
Naproxen
Naproxen sodium
oxaprozin
Oxaprozin
Penicillamine
Piroxicam
Piroxicam
Prednisolone
Prednisone
Ranitidine
Sodium aurothiomalate
solufenum
Sulfasalazine
Sulfasalazine
Sulindac
Sulindac
Tacrolimus
Tenoxicam
Tetracosactide
Thalidomide
Tiaprofenic acid
tocilizumab
tofacitinib
Tolmetin
Tolmetin
Tolmetin Sodium
Triamcinolone
valdecoxib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Rheumatoid Arthritis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: arthritis, rheumatoid

Genetic Tests for Rheumatoid Arthritis

Genetic tests related to Rheumatoid Arthritis:

# Genetic test Affiliating Genes
1 Rheumatoid Arthritis 29 CD244 CIITA IL10 NFKBIL1 PADI4 PTPN22 SLC22A4

Anatomical Context for Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Rheumatoid Arthritis:

41
Bone, T Cells, Lung, Testes, Endothelial, B Cells, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Rheumatoid Arthritis:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Temporomandibular Joint Affected by disease

Publications for Rheumatoid Arthritis

Articles related to Rheumatoid Arthritis:

(show top 50) (show all 33366)
# Title Authors PMID Year
1
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. 9 8 71
19898480 2009
2
Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. 38 8 71
18794858 2008
3
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. 9 8 71
17599733 2007
4
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. 9 8 71
15208781 2004
5
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 8 71
17554300 2007
6
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. 8 71
17436241 2007
7
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. 8 71
14608356 2003
8
Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. 8 71
12509789 2003
9
A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. 9 38 8
20453841 2010
10
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. 9 38 8
18794853 2008
11
BLyS and APRIL in rheumatoid arthritis. 9 38 8
16239971 2005
12
Genetics of rheumatoid arthritis contributes to biology and drug discovery. 38 8
24390342 2014
13
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. 38 8
20453842 2010
14
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. 38 8
19898481 2009
15
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. 9 8
19503088 2009
16
Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. 9 8
18759272 2008
17
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. 9 38 88
18759964 2008
18
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. 38 8
17982456 2007
19
Rheumatoid arthritis association at 6q23. 38 8
17982455 2007
20
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. 9 71
17170052 2007
21
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. 9 71
16273109 2005
22
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. 9 8
16175503 2005
23
4-1BB-mediated immunotherapy of rheumatoid arthritis. 38 8
15448685 2004
24
Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. 9 8
14558082 2003
25
Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. 9 8
12847677 2003
26
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. 9 8
11477412 2001
27
Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. 38 8
11369787 2001
28
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. 38 8
11254450 2001
29
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. 38 8
9724775 1998
30
Rheumatoid arthritis. 38 8
8616886 1996
31
Genetic epidemiology of rheumatoid arthritis. 38 8
7611283 1995
32
HLA-linked rheumatoid arthritis. 38 8
7942852 1994
33
Heredofamilial deficiency of monocyte esterase in patients with rheumatoid arthritis. 38 8
1616336 1992
34
The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. 38 8
2446635 1987
35
Different HLA-D associations in adult and juvenile rheumatoid arthritis. 38 8
762241 1979
36
FAMILIAL FACTORS IN RHEUMATOID ARTHRITIS. 38 8
14120603 1964
37
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. 8
25324392 2014
38
Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. 8
24786080 2014
39
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. 8
22290871 2012
40
The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. 71
21841778 2011
41
Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. 8
21211616 2011
42
MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. 38 88
20840794 2010
43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. 8
20360734 2010
44
Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. 8
20110505 2010
45
Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. 8
19359276 2009
46
Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. 8
19417005 2009
47
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. 71
19430480 2009
48
Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. 71
19265110 2009
49
Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. 71
18978792 2008
50
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. 71
18301444 2008